As a result, pregabalin was almost twice as likely as placebo to be discontinued because of adverse events (relative risk 1.91 [95% CI 1.54–2.37], p<0.00001).

Pregabalin did have beneficial effects on some symptoms of neuropathic pain.

Patients who took the drug reported significant reductions in pain and sleep interference scores compared with placebo (p < 0.00001 for both). However, the authors highlight that the overall quality of the evidence was low and the trials were of short duration.